ArticleDiseases (Basel, Switzerland)2026
Real-World Pharmacological Patterns and Residual Cardiometabolic Risk in Patients with Type 2 Diabetes in Romania.
Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundContemporary management of type 2 diabetes mellitus (T2DM) has shifted from a glucose-centered approach toward integrated cardio-renal-metabolic protection. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and intensive lipid-lowering therapies have demonstrated substantial cardiovascular and renal benefits, implementation in routine outpatient care and the burden of persistent residual risk remain insufficiently characterized in Romania.
objectivesWe aimed to evaluate routine-care pharmacological treatment patterns, identify residual cardio-renal-metabolic risk despite ongoing therapy, determine independent correlates of persistent adverse outcomes, and explore potential therapeutic gaps in adults with T2DM.
methodsThis cross-sectional observational study included 232 unique adults with T2DM attending a specialized outpatient diabetes clinic in Romania between 1 October 2024 and 19 February 2026. One eligible outpatient record per participant was analyzed; when multiple records were available, the earliest eligible record in the exported dataset was used as the index visit. No a priori sample-size calculation was performed. Pharmacological therapies, cardiovascular and renal phenotypes, metabolic biomarkers, and clinical outcomes were extracted from routinely collected electronic medical records. Residual risk was evaluated using glycemic, lipid, renal, obesity, and blood-pressure targets. Multivariable logistic regression analyses identified independent correlates of persistent cardio-metabolic abnormalities. An exploratory cumulative residual-risk count was constructed by summing seven clinically relevant uncontrolled risk factors.
resultsBiguanides were the most frequently prescribed glucose-lowering agents (53.0%), followed by SGLT2 inhibitors (44.8%), insulin (32.3% of the total cohort), GLP-1 receptor agonists (15.5%), and DPP-4 inhibitors (14.7%). Statins were prescribed to 48.7% of participants. SGLT2 inhibitor use did not differ significantly according to established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease phenotypes, whereas GLP-1 receptor agonists were prescribed more frequently in participants with obesity (22.0% vs. 7.6%,
conclusionsSignificant residual cardio-renal-metabolic risk persists in adults with T2DM despite use of contemporary pharmacological therapies. Disease severity markers and treatment exposure were associated with persistent adverse outcomes, but the cross-sectional design does not establish causality. The study identified potentially modifiable therapeutic gaps among patients with established cardiovascular and renal disease. Comprehensive and repeatedly reassessed cardio-renal-metabolic management, integrating pharmacological optimization with individualized risk stratification, may improve implementation of guideline-directed therapy and reduce long-term complications in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.